Silica calcium phosphate is a bioceramic material that has scientific backing for use in bone regeneration and repair, which underpins its application in the context of osteoporosis. Osteoporosis is characterized by decreased bone density and increased fracture risk. While silica calcium phosphate is not a standard systemic treatment (like bisphosphonates or denosumab), it is used in orthopedics and dentistry as a bone substitute or scaffold in cases where bone loss or fractures have occurred, including those resulting from osteoporosis.

Several preclinical and clinical studies have demonstrated that calcium phosphate ceramics, particularly when doped with silica, improve bone formation and integration. Silica enhances the bioactivity and osteoconductivity of calcium phosphate materials, promoting recruitment and differentiation of osteoblasts, and encouraging new bone matrix deposition. Reviews and experimental models indicate that these materials can support bone healing in osteoporotic conditions, but the evidence primarily supports local rather than systemic use.

Limitations include the fact that there are relatively few large, long-term randomized controlled trials specifically investigating silica calcium phosphate in the direct treatment or prevention of osteoporosis at the systemic level. Most evidence supports its use as a local bone graft or scaffold material. Therefore, while there is a scientific rationale and supportive experimental evidence for its role in managing osteoporosis-related bone defects, it is not a primary or direct therapy for the underlying disease process.